BlogHeader.png

The Importance of Secondary Packaging

There are three main types of packaging – primary, secondary, and tertiary – and it is important to understand that all levels of packaging serve specific purposes with specific requirements, in order to get products to people safely, efficiently, and consistently. Primary packaging is what directly encases and contains the drug product. Secondary packaging is the exterior packaging of the primary packaging that groups packages and further protects or labels the drug product. Tertiary packaging is used for bulk handling, storage, and distribution. An example of these packaging levels in the pharmaceutical industry are a vial or blister (primary packaging) placed into a carton (secondary packaging), then packed into a shipping case (tertiary packaging). This article will focus on secondary packaging and the importance of selecting a supplier who is well equipped to handle a product’s unique and customized packaging needs.  

Topics: Thought Leadership Serialization Oral Solid Dose Packaging

Editorial: The Changing R&D Landscape

Dr. Imran Ahmed, Head of Formulation Development at Alcami, recently published an article in Pharma Tech Outlook. The article, The Changing R&D Landscape: Emerging Technology Needs and Value Proposition for Strategic Partnerships with Contract Development and Manufacturing Organizations (CDMOs), explains that as a result of pharmaceutical products becoming increasingly complex, new regulatory and manufacturing challenges are on the rise.

Excerpt from Ahmed: "The pharmaceutical product landscape is rapidly and fundamentally changing with profound impact on research and development strategy and technology needs. After a precipitous fall in new drug approvals during the last two decade of the 20th century, there has been a gradual recovery going into the second decade of the 21st century."

Topics: Thought Leadership Regulatory Compliance Editorials Development R&D

Editorial: How to Find Your Secret Source

Alcami recently contributed to a special feature in The Medicine Maker magazine, titled "How to Find Your Secret Source."

Excerpt from Alcami: “I have a point of contention with the titles  ‘one-stop shop' or 'specialist supply chain’ because they imply that you can’t have both! If you have independent API and drug product, you can bring these together. Being that we were founded by merging two specialized organizations, we have experts in each area, which we then over arch with a structured offering to make sure they are properly integrated. A key thing our clients tell us – especially smaller clients who don’t want to manage a big supply chain – is that they like the internal efficiencies you can get with a one-stop shop."

Topics: Thought Leadership Supply Chain Editorials

Editorial: Considerations for Approval of Biosimilars

Alcami recently contributed to a special feature in the August / September issue of Chemicals Knowledge magazine, titled "Considerations for Approval of Biosimilars."

Biosimilars are sometimes incorrectly considered equivalent to a generic small molecule therapeutic, but for a biologic drug product, the clinical and regulatory pathways are quite different. Alcami Commercial Development Manager Cheryl Johnson explains the distinct differences in the FDA’s definition, development strategy, and regulatory approval pathways.

Topics: Thought Leadership Regulatory Compliance Biologics Editorials Parenteral Manufacturing

eBook: Analytical Testing in Drug Development

Alcami recently contributed to an eBook produced by Drug Development and Delivery. The eBook, titled "Analytical Testing in Drug Development," features four companies and explains how they each help the pharmaceutical and biotech industries comply with drug development regulatory requirements. 

Angela Moore, abuse-deterrence studies subject matter expert at Alcami, contributed to the eBook. Her article focuses on considerations for abuse-deterrent Category 1 studies as well as standard syringeability studies.

Topics: Thought Leadership Regulatory Compliance Abuse-Deterrence Editorials Development

Analytics in Solid State Chemistry: What You Need to Know

Solid state chemistry is fundamental to the development of a pharmaceutical compound into a drug product, and understanding analytics is crucial to successfully addressing any challenges that can occur in a product’s lifecycle. In solid state chemistry specifically, the physical and chemical (PhysChem) analytics will show which properties need to be improved to help ensure the highest chances of success: purity, stability, solubility, or bioavailability.

In drug development, knowing the characteristics of each form of the active pharmaceutical ingredient (API) is essential in order to select the most suitable form for production. For the research chemist, the PhysChem purity is one of the most crucial requirements. Furthermore, selection of the thermodynamically most stable polymorph; low hygroscopicity measured by dynamic vapor sorption (DVS); consistent crystallinity measured using X-ray powder diffraction (XRPD); sharp single melting event determined by differential scanning calorimetry (DSC); and low levels of residual solvent by thermogravimetric analysis (TGA) are all part of the ranking criteria. Aqueous solubility and dissolution rate are indispensable for the route of delivery and dosage form.

Topics: Thought Leadership Solid State API

A 3-Minute Introduction To Rapid Sterility Testing

Rapid sterility is an alternative test method to the US Pharmacopeia (USP) General Chapter <71>, Ph.Eur. 2.6.1, and JP 4.06 sterility tests that allows for shorter incubation periods and faster results. A typical sterility test has 14 full days of incubation and uses analyst observations to generate results, whereas a rapid sterility test is reduced to just five days of incubation – a 64% reduction in processing time. Rapid sterility also incorporates more sophisticated, computer-generated results, which eliminate observation bias. Alcami utilizes the Milliflex® Rapid System for the rapid sterility test, which uses adenosine triphosphate (ATP) bioluminescence for detection of microorganisms after five days.

Topics: Thought Leadership Analytical Testing Microbiology Rapid Sterility

Introduction to Quality by Design

Since Joseph Juran’s concept of Quality by Design (QbD) was first adopted by the US Food and Drug Administration (FDA), the pharmaceutical industry has been interpreting its concepts into a variety of approaches for implementation. At Alcami, our QbD approach considers evolving global regulatory guidances with a collaborative fit-for-purpose and pragmatic approach that can evolve throughout the lifecycle of the product. QbD starts from day one in modern product development, culminating in a chemistry manufacturing controls (CMC) package that maximizes every opportunity for a successful regulatory review and approval. The value of this approach is simple: design of robust processes for the consistent production of safe and effective products for our patients and long term cost savings for our partners through improved yields, reduced deviations, and efficient change management.

The QbD process for product development is intended to build quality into pharmaceuticals based on characteristics that define safety and efficacy. Critical quality attributes (CQAs) – specific physical, chemical, biological, and other properties – may impact product safety and efficacy and can be managed by identifying critical process parameters (CPPs) through the use of risk management tools and controlling them within the proven acceptable process design space.

Topics: Thought Leadership Regulatory Compliance Manufacturing Development Drug Product

Editorial: Enabling Technologies Advance Poorly Soluble Highly Potent APIs

Alcami recently contributed to a special feature in Pharmaceutical Technology magazine, titled "Enabling Technologies Advance Poorly Soluble Highly Potent APIs."

Excerpt from Alcami: In fact, challenges in containment can limit the technology that can be deployed for solubility enhancement, according to Adam Kujath, global senior director of manufacturing science and technology at Alcami. “Typical API approaches for solid dosage forms to improve solubility like micronization and spray drying are more difficult to outfit with appropriate containment systems. For instance, milling of solids, while not impossible to do in appropriate containment, poses a challenge since it tends to create dust in the breathing airspace for any worker. For parenteral formulations, lyophilization presents a similar challenge,” he says.

Topics: Thought Leadership HPAPI Editorials API Formulations

Regulatory Requirements for Early Phase Drug Product Development

Supporting a compound from discovery to clinical phases and potentially commercial phases requires an immense amount of time, energy, and money. Regulatory management is paramount during the drug development pipeline funnel, and recognizing Current Good Manufacturing Practices (CGMPs) is the foundation of drug safety and efficacy.

Every country has its own regulatory authority, responsible for enforcing rules and regulations and issuing guidelines for drug development, licensing, registration, manufacturing, marketing, and labeling of pharmaceutical products.[1]

Topics: Thought Leadership Regulatory Compliance Drug Product